NCT02217904View on ClinicalTrials.gov

A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 17, 2015

Primary Completion Date

May 11, 2017

Study Completion Date

May 11, 2017

Conditions
HIV-1
Interventions
DRUG

1 mg islatravir

Single oral dose of 1 mg islatravir administered following ≥8 hour fast

DRUG

2 mg islatravir

Single oral dose of 2 mg islatravir administered following ≥8 hour fast

DRUG

10 mg islatravir

Single oral dose of 10 mg islatravir administered following ≥8 hour fast

DRUG

30 mg islatravir

Single oral dose of 30 mg islatravir administered following ≥8 hour fast

DRUG

0.5 mg islatravir

Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast

DRUG

0.25 mg islatravir

Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02217904 - A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) | Biotech Hunter | Biotech Hunter